The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
Open accessAbstract
Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, and nonpharmacological approaches are useful and should be tried first. Pathophysiology‐based pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries and are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies, summarize the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs, and provide practical advice and management algorithms for clinicians, with focus on neurogenic orthostatic hypotension, supine hypertension, dysphagia, sialorrhea, gastroparesis, constipation, neurogenic overactive bladder, underactive bladder, and sexual dysfunction. © 2018 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Self-citationFreeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., Cheshire, W. P., Chelimsky, T., Cortelli, P., Gibbons, C. H., et al. (2011) · Clinical Autonomic Research · doi:10.1007/s10286-011-0119-5 · Cited by 1,697
Self-citationFreeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., Cheshire, W. P., Chelimsky, T., Cortelli, P., Gibbons, C. H., et al. (2011) · Autonomic Neuroscience · doi:10.1016/j.autneu.2011.02.004 · Cited by 1,243
Self-citationα-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Vagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806
Low, P. A. (1997) · JAMA · doi:10.1001/jama.1997.03540370036033 · Cited by 425
Pan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'Sullivan, G. A., Pal, A., Said, J., Marsico, G., Verbavatz, J.-M., Rodrigo-Angulo, M., et al. (2012) · Scientific Reports · doi:10.1038/srep00898 · Cited by 405
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine
Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., Rubin, M., & Fouad-Tarazi, F. M. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90230-m · Cited by 396
Self-citationProbiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003127 · Cited by 390
Neurogenic Orthostatic Hypotension
Freeman, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp074189 · Cited by 384
Two randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373 · cited 1×
“Although it has not been specifically studied in patients with synucleinopathies, randomized, placebo-controlled trials performed in subjects with chronic constipation showed that 290 or 145 lg of linaclotide once-daily 30 minutes before breakfast significantly increased daily spontaneous bowel movements.(174) Potenti…”
ResultMultiple organ involvement by alpha-synuclein pathology in lewy body disorders
Gelpi, E., Navarro‐Otano, J., Tolosa, E., Gaig, C., Compta, Y., Rey, M. J., Martí, M. J., Hernández, I., Valldeoriola, F., Reñé, R., et al. (2014) · Movement Disorders · doi:10.1002/mds.25776 · Cited by 361
EFNS guidelines on the diagnosis and management of orthostatic hypotension
Lahrmann, H., Cortelli, P., Hilz, M., Mathias, C. J., Struhal, W., & Tassinari, M. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01512.x · Cited by 334 · cited 1×
“Consensus guidelines for the treatment of nOH are available.(36,37) The steps of nOH management include: (1) correcting aggravating factors; (2) implementing nonpharmacological measures; and (3) drug therapies.”
BackgroundA double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
Wright, R. A., Kaufmann, H. C., Perera, R., Opfer-Gehrking, T. L., McElligott, M. A., Sheng, K. N., & Low, P. A. (1998) · Neurology · doi:10.1212/wnl.51.1.120 · Cited by 331
Self-citationAssociation between supine hypertension and orthostatic hypotension in autonomic failure
Goldstein, D. S., Pechnik, S., Holmes, C., Eldadah, B., & Sharabi, Y. (2003) · Hypertension · doi:10.1161/01.hyp.0000081216.11623.c3 · Cited by 233
Kamaruzzaman, S., Watt, H., Carson, C., & Ebrahim, S. (2010) · Age and Ageing · doi:10.1093/ageing/afp192 · Cited by 182
Zangaglia, R., Martignoni, E., Glorioso, M., Ossola, M., Riboldazzi, G., Calandrella, D., Brunetti, G., & Pacchetti, C. (2007) · Movement Disorders · doi:10.1002/mds.21243 · Cited by 177
Smit, A. J., Wieling, W., Fujimura, J., Denq, J., Opfer-Gehrking, T., Akarriou, M., Karemaker, J., & Low, P. (2004) · Clinical Autonomic Research · doi:10.1007/s10286-004-0187-x · Cited by 153
Miner, P. B., Koltun, W. D., Wiener, G. J., De La Portilla, M., Prieto, B., Shailubhai, K., Layton, M. B., Barrow, L., Magnus, L., & Griffin, P. H. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.611 · Cited by 141 · cited 1×
“Plecanatide, another oral guanylate cyclase-C receptor agonist, also showed efficacy in placebo-controlled, randomized trials to increase spontaneous bowel movements.(175,176) It was FDA approved in 2017 for the treatment of chronic idiopathic constipation and may prove useful in patients with synucleinopathies.”
Physical manoeuvres that reduce postural hypotension in autonomic failure
Wieling, W., van Lieshout, J. J., & van Leeuwen, A. M. (1993) · Clinical Autonomic Research · doi:10.1007/bf01819146 · Cited by 140
A prospective study of bowel movement frequency and risk of Parkinson's disease
Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr119 · Cited by 115
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease
Ondo, W. G., Kenney, C., Sullivan, K., Davidson, A., Hunter, C., Jahan, I., McCombs, A., Miller, A., & Zesiewicz, T. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182574f28 · Cited by 112
Okamoto, L. E., Diedrich, A., Baudenbacher, F. J., Harder, R., Whitfield, J. S., Iqbal, F., Gamboa, A., Shibao, C. A., Black, B. K., Raj, S. R., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07199 · Cited by 79
Hepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity Disorder
Bangs, M. E., Jin, L., Zhang, S., Desaiah, D., Allen, A. J., Read, H. A., Regev, A., & Wernicke, J. F. (2008) · Drug Safety · doi:10.2165/00002018-200831040-00008 · Cited by 68
Orthostatic hypotension and anti-hypertensive therapy in the elderly
Fotherby, M. D., & Potter, J. F. (1994) · Postgraduate Medical Journal · doi:10.1136/pgmj.70.830.878 · Cited by 54
Cited by
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Chen, Z., Li, G., & Liu, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 363
New evidence on the management of Lewy body dementia
Taylor, J.-P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., Allan, L. M., Thomas, A. J., & O'Brien, J. T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30153-x · Cited by 347
Poewe, W., Stankovic, I., Halliday, G., Meissner, W. G., Wenning, G. K., Pellecchia, M. T., Seppi, K., Palma, J.-A., & Kaufmann, H. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00382-6 · Cited by 279
Self-citationLorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Metadata
- Authors
- Palma, J., & Kaufmann, H.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2018-03
- Volume
- 33
- Issue
- 3
- Pages
- 372-390
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2792783253
- Cited by
- 245
- References
- 27
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.